Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Kain, Vasundhara ^a,c   Kapadia, Bandish ^a   Misra, Parimal ^a   Saxena, Uday ^b  

^a UNIVERSITY OF HYDERABAD   (India)

^b Kareus Therapeutics   (Switzerland)

^c University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIMVASTATIN;

DRUG EFFECTS; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; METABOLISM; SIGNAL TRANSDUCTION;

CHOLESTEROL; FATTY ACIDS; GLUCOSE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN; INSULIN RESISTANCE; MEVALONIC ACID; PPAR GAMMA; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 84941133525     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13823     Document Type: Article

References (40)

1. Mol, M. J., Erkelens, D. W., Leuven, J. A., Schouten, J. A. & Stalenhoef, A. F. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet 2, 936-939 (1986).
2. Tobert, J. A. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76, 534-538 (1987).
3. Simons, L. A., Nestel, P. J., Calvert, G. D. & Jennings, G. L. Effects of MK-733 on plasma lipid and lipoprotein levels in subjects with hypercholesterolaemia. Med J Aust 147, 65-68 (1987).
4. Walker, J. F. & Tobert, J. A. The clinical efficacy and safety of lovastatin and MK-733 - an overview. Eur Heart J 8 Suppl E, 93-96 (1987).
5. Olsson, A. G., Molgaard, J. & von Schenk, H. Synvinolin in hypercholesterolaemia. Lancet 2, 390-391 (1986).
6. Tikkanen, M. J. & Nikkila, E. A. Current pharmacologic treatment of elevated serum cholesterol. Circulation 76, 529-533 (1987).
7. Illingworth, D. R. & Sexton, G. J. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 74, 1972-1978, doi: 10.1172/JCI111618 (1984).
8. Hoeg, J. M. et al. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am J Cardiol 57, 933-939 (1986).
9. Grundy, S. M. & Vega, G. L. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 26, 1464-1475 (1985).
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339, 1349-1357, doi: 10.1056/NEJM199811053391902 (1998).
11. Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333, 1301-1307, doi: 10.1056/NEJM199511163332001 (1995).
12. Pedersen, T. R. et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 5, 81-87, doi: 10.1016/j.atherosclerosissup.2004.08.027 (2004).
13. Pedersen, T. R. et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86, 257-262 (2000).
14. Pedersen, T. R. et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156, 2085-2092 (1996).
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
16. Miettinen, T. A. et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 96, 4211-4218 (1997).
17. Willerson, J. T. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 94, 3054 (1996).
18. Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742, doi: 10.1016/S0140-6736(09)61965-6 (2010).
19. Corrao, G. et al. Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study. Diabetes Care. doi: 10.2337/dc13-2215 (2014).
20. Macedo, A. F., Douglas, I., Smeeth, L., Forbes, H. & Ebrahim, S. Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink. BMC Cardiovasc Disord 14, 85, doi: 10.1186/1471-2261-14-85 (2014).
21. Bell, D. S., DiNicolantonio, J. J. & O'Keefe, J. H. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. Diabetes Obes Metab 16, 689-694, doi: 10.1111/dom.12254 (2014).
22. Rajpathak, S. N. et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 32, 1924-1929, doi: 10.2337/dc09-0738 (2009).
23. Amarenco, P., Labreuche, J., Lavallee, P. & Touboul, P. J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35, 2902-2909, doi: 10.1161/01.STR.0000147965.52712.fa (2004).
24. Davidson, M. H. Pharmacotherapy: Implications of high-dose statin link with incident diabetes. Nat Rev Cardiol 8, 543-544, doi: 10.1038/nrcardio.2011.118 (2011).
25. Goldfine, A. B. Statins: is it really time to reassess benefits and risks? N Engl J Med 366, 1752-1755, doi: 10.1056/NEJMp1203020 (2012).
26. Brault, M., Ray, J., Gomez, Y.-H., Mantzoros, C. S. & Daskalopoulou, S. S. Statin treatment and new-onset diabetes: A review of proposed mechanisms. Metabolism 63, 735-745, http://dx.doi.org/10.1016/j.metabol.2014.02.014 (2014).
27. + channels in rat islet beta-cells. Br J Pharmacol 126, 1205-1213, doi: 10.1038/sj.bjp.0702397 (1999).
28. Nakata, M. et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49, 1881-1892, doi: 10.1007/s00125-006-0269-5 (2006).
29. Larsen, S. et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol 61, 44-53, doi: 10.1016/j.jacc.2012.09.036 (2013).
30. Ragheb, R. et al. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun 389, 211-216, doi: 10.1016/j.bbrc.2009.08.106 (2009).
31. Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266, 15771-15781 (1991).
32. Middleton, B. The kinetic mechanism and properties of the cytoplasmic acetoacetyl-coenzyme A thiolase from rat liver. Biochem J 139, 109-121 (1974).
33. Slater, E. E. & MacDonald, J. S. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 Suppl 3, 72-82 (1988).
34. Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340 (1997).
35. Loftus, T. M. et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288, 2379-2381 (2000).
36. Brault, M., Ray, J., Gomez, Y. H., Mantzoros, C. S. & Daskalopoulou, S. S. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63, 735-745, doi: 10.1016/j.metabol.2014.02.014 (2014).
37. Leira, F., Louzao, M. C., Vieites, J. M., Botana, L. M. & Vieytes, M. R. Fluorescent microplate cell assay to measure uptake and metabolism of glucose in normal human lung fibroblasts. Toxicol In Vitro 16, 267-273 (2002).
38. Kewalramani, G., Fink, L. N., Asadi, F. & Klip, A. Palmitate-activated macrophages confer insulin resistance to muscle cells by a mechanism involving protein kinase C theta and epsilon. PLoS One 6, e26947, doi: 10.1371/journal.pone.0026947 (2011).
39. Kapadia, B. et al. ERK2-mediated phosphorylation of transcriptional coactivator binding protein PIMT/NCoA6IP at Ser298 augments hepatic gluconeogenesis. PLoS One 8, e83787, doi: 10.1371/journal.pone.0083787 (2013).
40. Li, X. et al. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One 8, e70987, doi: 10.1371/journal.pone.0070987 (2013).